Skip to main content

HubXchange

HubXChange logo

News Xchange

Page Banner 1

Raising the Bar: Analytical Separation’s Role in Ensuring Quality & Scale for RNA-LNP Therapeutics

Introduction

RNA medicines are advancing rapidly, from mRNA vaccines to siRNA and CRISPR-based therapies. Lipid nanoparticles (LNPs) remain the backbone of delivery, but characterizing these complex systems at scale is a growing bottleneck.

A recent review (Drennan & Schug, 2025) underscores that analytical separation is no longer a supporting tool — it has become a strategic capability that will shape development timelines, regulatory outcomes, and competitiveness in RNA therapeutics [1].

Why Heterogeneity Cannot Be Ignored

Every batch of RNA-LNPs contains hidden variability in particle size, lipid composition, encapsulation efficiency, and RNA integrity. Conventional assays such as Dynamic Light Scattering (DLS) and RiboGreen can obscure this heterogeneity, leaving subpopulations undetected [1].

For senior leaders, this represents more than a technical nuance — it is a risk exposure with potential to cause batch failures, regulatory pushback, or unstable clinical outcomes.

The Limits of Traditional QC

  • DLS reports average particle size but is biased by aggregates and blind to mixed populations [1].

  • RiboGreen assays measure total RNA but fail to distinguish between free, degraded, or fully encapsulated molecules [1].

These methods are useful for early-stage work but are insufficient as GMP-quality analytics.

Separation Techniques Are Advancing

The analytical toolbox is evolving rapidly:

  • Chromatography — ion-exchange, HILIC, and mixed-mode columns enable separation of intact RNA from fragments [2].

  • Electrophoresis — capillary and chip-based systems provide detailed readouts of RNA integrity [3].

  • Field-flow fractionation (AF4) with detectors like MALS or SAXS delivers high-resolution particle profiling [4].

  • Orthogonal strategies — combining techniques to cross-validate data, reduce blind spots, and build regulatory confidence [1].

Gaps That Remain

Despite progress, challenges persist:

  • Validation and regulatory alignment — many separation techniques are not yet standardized for GMP use [1].

  • Throughput vs. resolution — high-resolution methods remain too slow for routine QC [1].

  • Novel formulations — new lipid chemistries and RNA payloads are outpacing validated assays [5].

For leadership, the message is clear: analytics must evolve alongside innovation.

Strategic Questions for Leaders

  • Are we investing early enough in analytics? Late adoption leads to costly course corrections.

  • Do we have the right partnerships? Not every CDMO has advanced separation expertise.

  • Are we aligned with regulators? Early engagement reduces risk of delays.

  • Are we balancing speed with precision? Discovery-phase assays are fine, but GMP requires orthogonal methods.

  • Do we know our blind spots? Free RNA, aggregates, or ligand-modified LNPs often go undetected without advanced separation [1,4].

The Competitive Edge

Emerging evidence shows that companies using AF4 with multi-detectors, advanced HILIC workflows, and mild stationary phases are achieving results that can integrate into GMP pipelines [2,4].

In a competitive market, analytics is no longer a cost center — it is a differentiator that drives fewer batch failures, faster scale-up, and stronger regulatory confidence.

Conclusion

For senior scientists and executives, the conclusion is clear: analytical separation is now a board-level issue. Organizations that act early — embedding separation science into development and aligning with regulators — will accelerate programs and de-risk commercialization.

In RNA therapeutics, analytics will separate leaders from followers.

 

 

References

 

View all News Xchange
Loading
Search